Updates from ASCO 2024

Each year, The Patient Story attends a handful of cancer conferences to meet with experts on the frontlines of cancer care and report on developments that matter to patients. We’ve reported on ASH, SABCS, and ASCOThe American Society for Clinical Oncology (ASCO), established in 1964, plays a pivotal role in the global fight against cancer.  It was held from May 31 to June 4, 2024. This page provides updates from our attendance. 

Conquering Cancer: The Impact of ASCO on Patient Care

The American Society for Clinical Oncology (ASCO) and its annual meeting unites over 40,000 professionals from more than 100 countries across various oncology subspecialties and disciplines around the world, all committed to advancing cancer care. This premier organization is at the forefront of fostering innovative research, disseminating critical educational resources, and advocating for high-quality patient care. And we were there.

Top ASCO News for Patients

Early stage breast cancer

Docetaxel causes less peripheral neuropathy compared to paclitaxel for Black patients with early-stage breast cancer, potentially making it the preferred treatment.

Limited-stage small cell lung cancer

Durvalumab after chemoradiotherapy significantly improves survival for people with limited-stage small cell lung cancer - receiving a standing ovation.

Non-small cell lung cancer

Osimertinib after chemoradiotherapy extends progression-free survival for stage III NSCLC patients with EGFR mutations.

Stage 3 melanoma

Combining ipilimumab and nivolumab before surgery, followed by selective adjuvant therapy, improves outcomes for stage III melanoma patients.

RR multiple myeloma

A combination of belantamab mafodotin, pomalidomide, and dexamethasone shows promise in treating relapsed or refractory multiple myeloma.

Breast cancer and fertility

Many breast cancer survivors successfully conceive and give birth post-treatment.

Advanced ovarian cancer

Some advanced ovarian cancer patients may avoid lymph node removal during surgery safely.

Colorectal cancer

An AI-based patient navigation tool may help reduce barriers to colorectal cancer screening in underserved communities.

Hodgkin lymphoma

A new treatment combination cures classical Hodgkin lymphoma more effectively and with fewer side effects than intensive chemotherapy.

Chronic myeloid leukemia

Targeted therapy drug asciminib is a safe and effective treatment for chronic phase chronic myeloid leukemia.

ALK-positive nsc lung cancer

Lorlatinib outperforms crizotinib in stopping progression of ALK-positive non-small cell lung cancer.

Metastatic breast cancer

Trastuzumab deruxtecan slows cancer growth in HR+, HER2-low or HER2-ultralow metastatic breast cancer.

Top Stories

Taxol, Hair Loss & The Inevitable New ‘Do

Why does losing one’s hair cause a waterfall of tears? Read the deeply personal stories of cancer survivors' hair loss and regrowth...

Clinical Trial Expert Interviews